US FDA seeks comments on Bacillus species IVD classification guidance
This article was originally published in RAJ Devices
The US Food and Drug Administration has issued for comment a draft special controls guidance document that supports its proposal to classify in vitro diagnostics for detecting Bacillus species as a Class II device1.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.
An advanced immunotherapy for recurrent glioblastoma and the first biosimilar version of Lucentis for age-related macular degeneration have also been submitted for review by the European Medicines Agency for potential pan-EU authorization.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.